Source-grounded facts extracted from ALNYLAM PHARMACEUTICALS, INC.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
ALNYLAM PHARMACEUTICALS, INC. shareholders approved Ratification of PricewaterhouseCoopers LLP as independent auditors at the 2026-12-31 meeting.
“3. The Company’s stockholders ratified the appointment by the Company’s Board of Directors of PricewaterhouseCoopers LLP as the Company’s independent auditors for the fiscal year ending December 31, 2026. The voting results were as follows: Votes For Votes Against Abstentions Broker Non-Votes 119,847,735 5,937,274 31,695 0”
ALNYLAM PHARMACEUTICALS, INC. shareholders approved Non-binding advisory vote on compensation of named executive officers.
“2. The Company’s stockholders approved, in a non-binding advisory vote, the compensation of the Company’s named executive officers. The voting results were as follows: Votes For Votes Against Abstentions Broker Non-Votes 111,772,389 8,552,534 41,495 5,450,286”
ALNYLAM PHARMACEUTICALS, INC. shareholders approved Re-election of three Class I directors.
“1. The Company’s stockholders re-elected the three persons listed below as Class I directors, each to serve until the Company’s 2029 annual meeting of stockholders or until his or her successor is duly elected and qualified. The voting results were as follows: Votes For Votes Against Abstentions Broker Non-Votes Stuart A. Arbuckle 115,269,659 5,068,463 28,296 5,450,286 Yvonne L. Greenstreet, M.D. 119,787,307 513,049 66,062 5,450,286 Elliott Sigal, M.D., Ph.D. 107,495,421 12,844,836 26,161 5,450,286”
Benjamin F. Cravatt was elected as Director at ALNYLAM PHARMACEUTICALS, INC..
“Effective as of June 1, 2026, the Board of Directors (the “Board”) of Alnylam Pharmaceuticals, Inc. (the “Company”), following the recommendation of its Nominating and Corporate Governance Committee, expanded the size of the Company’s Board from ten to eleven and elected Benjamin F. Cravatt, Ph.D. to fill the newly created vacancy.”
ALNYLAM PHARMACEUTICALS, INC. reported the first quarter ended March 31, 2026 results: revenue $1,036 Million. Guidance reaffirmed.
“Alnylam Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Period Progress − Achieved First Quarter 2026 Global Net Product Revenues of $1,036 Million”
ALNYLAM PHARMACEUTICALS, INC. incurred revolving credit of $500.0 million revolving line of credit with Bank of America, N.A., as Administrative Agent at term SOFR rate plus an applicable margin between 1.50% and 2.50% maturing September 30, 2030.
““Credit Agreement”) among the lenders party thereto, Bank of America, N.A., as Administrative Agent, and the other parties named therein. The Credit Agreement provides for a $500.0 million revolving line of credit (the “Revolving Credit Facility”), including a $150.0 million letter of credit sublimit. The Credit Agreement provides that the Company has the right at”
ALNYLAM PHARMACEUTICALS, INC. incurred convertible notes of $661.25 million with The Bank of New York Mellon at 0.00% maturing September 15, 2028.
“0.00% Convertible Senior Notes due 2028 (the “Additional Notes” and together with the Initial Notes, the “Notes”), bringing the total aggregate principal amount of the Notes to $661.25 million. The Notes are the Company’s senior unsecured obligations. The Notes were issued pursuant to an Indenture, dated September 12, 2025 (the “Indenture”), between the Company and The”
Pushkal Garg was appointed as Executive Vice President, Chief Research and Development Officer at ALNYLAM PHARMACEUTICALS, INC..
“the Committee approved (i) the appointment of Pushkal Garg, M.D., the Company’s current Chief Medical Officer, Executive Vice President, Development and Medical Affairs, to the position of Executive Vice President, Chief Research and Development Officer”
ALNYLAM PHARMACEUTICALS, INC.: Certificate of Amendment filed to allow for officer exculpation (effective 2025-05-08).
“the Company filed a Certificate of Amendment to the Company’s Restated Certificate of Incorporation to allow for officer exculpation (the “Certificate of Amendment”).”
Phillip A. Sharp retired as Director at ALNYLAM PHARMACEUTICALS, INC..
“On March 3, 2025, Phillip A. Sharp, Ph.D. informed the Board of Directors (the “Board”) of Alnylam Pharmaceuticals, Inc. (the “Company”) of his retirement from the Board, effective as of May 8, 2025.”
ALNYLAM PHARMACEUTICALS, INC. reported the quarter ended March 31, 2024 results: revenue $365 million, net income GAAP Net loss $65,935 (in thousands), EPS GAAP Net loss per common share - basic and diluted $0.52. Guidance reaffirmed.
“Alnylam Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Period Activity − Achieved First Quarter 2024 Global Net Product Revenues of $365 Million”
Indrani L. Franchini changed role as Executive Vice President, Chief Legal Officer and Secretary at ALNYLAM PHARMACEUTICALS, INC..
“Indrani L. Franchini agreed that she would transition from her role as the Company’s Executive Vice President, Chief Legal Officer and Secretary, effective as of March 1, 2024”
ALNYLAM PHARMACEUTICALS, INC. reported the fourth quarter and full year ended December 31, 2023 results: revenue $346 Million and $1,241 Million, Respectively.
“Achieved Fourth Quarter and Full Year 2023 Global Net Product Revenues of $346 Million and $1,241 Million, Respectively, Representing 39% Annual Growth Compared to 2022”
Indrani L. Franchini changed role as Executive Vice President, Chief Legal Officer and Secretary at ALNYLAM PHARMACEUTICALS, INC..
“On January 12, 2024, Alnylam Pharmaceuticals, Inc. (the “Company”) and Indrani L. Franchini agreed that she would transition from her role as the Company’s Executive Vice President, Chief Legal Officer and Secretary, effective as of March 1, 2024”
ALNYLAM PHARMACEUTICALS, INC. reported fourth quarter 2023 results: revenue $346 million.
“On January 7, 2024, Alnylam Pharmaceuticals, Inc. (the “Company”) announced its preliminary fourth quarter and full year 2023 global net product revenues of approximately $346 million and $1,241 million, respectively, for ONPATTRO® (patisiran), AMVUTTRA® (vutrisiran), GIVLAARI® (givosiran) and OXLUMO® (lumasiran).”
ALNYLAM PHARMACEUTICALS, INC. reported full year 2023 results: revenue $1,241 million.
“On January 7, 2024, Alnylam Pharmaceuticals, Inc. (the “Company”) announced its preliminary fourth quarter and full year 2023 global net product revenues of approximately $346 million and $1,241 million, respectively, for ONPATTRO® (patisiran), AMVUTTRA® (vutrisiran), GIVLAARI® (givosiran) and OXLUMO® (lumasiran).”
ALNYLAM PHARMACEUTICALS, INC. reported third quarter ended September 30, 2023 results: revenue $313 Million, net income $147,753, EPS $1.18.
“Alnylam Pharmaceuticals Reports Third Quarter 2023 Financial Results and Highlights Recent Period Activity − Achieved Third Quarter 2023 Global Net Product Revenues of $313 Million, Representing 35% Year-Over-Year Growth Compared to Q3 2022 –”
Marsha H. Fanucci resigned as Director at ALNYLAM PHARMACEUTICALS, INC..
“On September 26, 2023, Marsha H. Fanucci informed the Board of Directors (the “Board”) of Alnylam Pharmaceuticals, Inc. (the “Company”) of her resignation from the Board effective as of September 29, 2023.”
ALNYLAM PHARMACEUTICALS, INC. updated its the second quarter ended June 30, 2023 guidance (reaffirmed).
“On August 3, 2023, Alnylam Pharmaceuticals, Inc. (the “Company”) announced its financial results for the quarter ended June 30, 2023.”
Akshay K. Vaishnaw changed role as Chief Innovation Officer at ALNYLAM PHARMACEUTICALS, INC..
“On July 31, 2023, the Company and Akshay K. Vaishnaw, M.D., Ph.D. entered into a letter agreement (the “Letter Agreement”), whereby Dr. Vaishnaw will leave his current position as President of the Company and transition to a part-time role as Chief Innovation Officer, effective October 2, 2023 (the “Transition Date”).”
ALNYLAM PHARMACEUTICALS, INC. entered into Collaboration and License Agreement with F. Hoffmann-La Roche Ltd. and Genentech, Inc. valued at $310 million (effective 2023-07-21).
“On July 21, 2023 (the “ Effective Date ”), Alnylam Pharmaceuticals, Inc. (the “ Company ”), entered into a Collaboration and License Agreement (the “ Agreement ”) with F. Hoffmann-La Roche Ltd. (“ Roche Basel ”) and Genentech, Inc. (“ Genentech ,” each of Roche Basel and Genentech, individually and collectively, “ Roche ”)”
ALNYLAM PHARMACEUTICALS, INC. shareholders approved Ratification of appointment of PricewaterhouseCoopers LLP as independent auditors at the 2023-05-18 meeting.
“The Company’s stockholders ratified the appointment by the Company’s Board of Directors of PricewaterhouseCoopers LLP as the Company’s independent auditors for the fiscal year ending December 31, 2023.”
ALNYLAM PHARMACEUTICALS, INC. shareholders approved Advisory vote on frequency of future advisory votes on named executive officer compensation at the 2023-05-18 meeting.
“The Company’s stockholders recommended, in a non-binding advisory vote, a frequency of every One Year for future advisory stockholder votes on the compensation of the Company’s named executive officers.”
ALNYLAM PHARMACEUTICALS, INC. shareholders approved Advisory vote on named executive officer compensation at the 2023-05-18 meeting.
“The Company’s stockholders approved, in a non-binding advisory vote, the compensation of the Company’s named executive officers.”
ALNYLAM PHARMACEUTICALS, INC. shareholders approved Election of Class I Directors at the 2023-05-18 meeting.
“The Company’s stockholders re-elected the four persons listed below as Class I directors, each to serve until the Company’s 2026 annual meeting of stockholders or until his or her successor is duly elected and qualified.”
ALNYLAM PHARMACEUTICALS, INC. reported the first quarter ended March 31, 2023 results: revenue $276 Million. Guidance reaffirmed.
“− Achieved First Quarter 2023 Global Net Product Revenues of $276 Million, Representing 48% Year-Over-Year Growth Compared to Q1 2022 –”
Peter N. Kellogg was elected as Director at ALNYLAM PHARMACEUTICALS, INC..
“Effective as of March 7, 2023, the Board of Directors (the “Board”) of Alnylam Pharmaceuticals, Inc. (the “Company”), following the recommendation of its Nominating and Corporate Governance Committee, expanded the size of the Company’s Board from twelve to thirteen and elected Peter N. Kellogg to fill the newly created vacancy.”
ALNYLAM PHARMACEUTICALS, INC. reported the year ending December 31, 2023 results: revenue $1,200 Million to $1,285 Million. Guidance initiated.
“Provides 2023 Combined Net Product Revenue Guidance of $1,200 Million to $1,285 Million”
ALNYLAM PHARMACEUTICALS, INC. reported the year ended December 31, 2022 results: revenue $894 Million.
“Achieved Fourth Quarter and Full Year 2022 Global Net Product Revenues of $262 Million and $894 Million, Respectively”
ALNYLAM PHARMACEUTICALS, INC. reported the quarter ended December 31, 2022 results: revenue $262 Million.
“Achieved Fourth Quarter and Full Year 2022 Global Net Product Revenues of $262 Million and $894 Million, Respectively”
ALNYLAM PHARMACEUTICALS, INC. reported fourth quarter and full year 2022 results: revenue approximately $262 million and $894 million, respectively.
“On January 8, 2023, Alnylam Pharmaceuticals, Inc. (the “Company”) announced its preliminary fourth quarter and full year 2022 global net product revenues of approximately $262 million and $894 million, respectively, for ONPATTRO ® (patisiran), AMVUTTRA ® (vutrisiran), GIVLAARI ® (givosiran) and OXLUMO ® (lumasiran), and provided additional updates on the products’ commercial launches.”
Carolyn R. Bertozzi was elected as Director at ALNYLAM PHARMACEUTICALS, INC..
“Effective as of January 5, 2023, the Board of Directors (the “Board”) of Alnylam Pharmaceuticals, Inc. (the “Company”), following the recommendation of its Nominating and Corporate Governance Committee, expanded the size of the Company’s Board from eleven to twelve and elected Dr. Carolyn R. Bertozzi to fill the newly created vacancy.”
Dr. Elliott Sigal was elected as Director at ALNYLAM PHARMACEUTICALS, INC..
“Effective as of August 22, 2022, the Board of Directors (the “Board”) of Alnylam Pharmaceuticals, Inc. (the “Company”), following the recommendation of its Nominating and Corporate Governance Committee, expanded the size of the Company’s Board from ten to eleven and elected Dr. Elliott Sigal to fill the newly created vacancy.”
Steven M. Paul resigned as Director at ALNYLAM PHARMACEUTICALS, INC..
“On March 31, 2022, Steven M. Paul, M.D. informed the Board of Directors (the “Board”) of Alnylam Pharmaceuticals, Inc. (the “Company”) of his resignation from the Board effective as of April 16, 2022.”
Yvonne L. Greenstreet was appointed as Chief Executive Officer at ALNYLAM PHARMACEUTICALS, INC..
“As previously announced, Yvonne L. Greenstreet, MBChB, MBA, the Company’s former President and Chief Operating Officer, was appointed Chief Executive Officer effective January 1, 2022.”
Akshay K. Vaishnaw was appointed as President at ALNYLAM PHARMACEUTICALS, INC..
“On January 4, 2022, Alnylam Pharmaceuticals, Inc. (the “Company”) announced that its Board of Directors (the “Board”) appointed Akshay K. Vaishnaw, M.D., Ph.D., the Company’s current President, Research and Development, as President effective January 1, 2022.”
Yvonne L. Greenstreet was appointed as Chief Executive Officer at ALNYLAM PHARMACEUTICALS, INC..
“Yvonne L. Greenstreet, MBChB, MBA, Alnylam Pharmaceuticals, Inc.’s (the “Company”) current President and Chief Operating Officer, has been appointed Chief Executive Officer of the Company effective January 1, 2022.”
Yvonne L. Greenstreet was appointed as Director at ALNYLAM PHARMACEUTICALS, INC..
“the Board expanded the size of the Board from eleven to twelve members and elected Dr. Greenstreet to fill the newly created vacancy, in each case effective as of October 28, 2021.”
John M. Maraganore departed as Chief Executive Officer at ALNYLAM PHARMACEUTICALS, INC..
“The Company also announced that, as part of this leadership transition, following nearly 19 years of service, John M. Maraganore, Ph.D., will depart from his position as Chief Executive Officer of the Company and as a member of the Board, effective December 31, 2021.”
Laurie B. Keating retired as Executive Vice President, Chief Legal Officer and Secretary at ALNYLAM PHARMACEUTICALS, INC..
“On September 6, 2021, Laurie B. Keating, a named executive officer of Alnylam Pharmaceuticals, Inc. (the “Company”), retired from the Company and resigned from her position as Executive Vice President, Chief Legal Officer and Secretary of the Company, effective September 10, 2021, following 7 years of service.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.